Multiple Myeloma Trial Landscape (October 2026)

Last updated: Oct 16, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov

Overview

Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.

Mechanism Breakdown

Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.

Recently Updated Trials

NCT	Phase	Title	Mechanism
NCT06904066	1	Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies	Patient-specific neoantigen TCRs -- autologous T cell receptor (TCR) transduced T cells
NCT05909059	2	CAR T-cell Therapy in Patients With Renal Dysfunction	Unknown mechanism
NCT06182774	3	Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma	CD38 + Cereblon + Glucocorticoid receptor -- monoclonal antibody + immunomodulatory drug + corticosteroid
NCT07648264	3	Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies	IgG replacement -- immunoglobulin therapy
NCT07874334	1	Phase 1a/b Study of GPRC5D CART Therapy in Relapsed/Refractory Multiple Myeloma and Light-chain Amyloidosis	GPRC5D -- chimeric antigen receptor T-cell therapy (CART)

Top Sponsors

Sponsor	Recruiting trials
Institute of Hematology & Blood Diseases Hospital, China	29
Regeneron Pharmaceuticals	11
Memorial Sloan Kettering Cancer Center	11
Janssen Research & Development, LLC	11
Xuzhou Medical University	9

Geographic Distribution

Countries/regions with the most active trial sites for multiple myeloma. A multi-site trial is counted once per country/region.

Emerging Classes

Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.

Start	NCT	Title	Mechanism
Jun 30, 2027	NCT06435910	Engineered Dendritic Cell Vaccines for Multiple Myeloma	Tumor antigens -- dendritic cell vaccine
Jun 30, 2027	NCT06006741	Universal CAR-T Cells Targeting Multiple Myeloma	Multiple myeloma antigens -- universal chimeric antigen receptor T cell therapy (CAR-T)
Apr 12, 2027	NCT07463807	Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment	BCMA + CD3 -- bispecific antibody (teclistamab); Cereblon modulator (pomalidomide); Proteasome inhibitor (carfilzomib)
Dec 31, 2026	NCT06429150	Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma	Multiple myeloma antigens -- CAR-T cell therapy
Dec 31, 2026	NCT03271632	Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma	Multiple cancer cell surface antigens -- chimeric antigen receptor (CAR) T cell therapy
Dec 1, 2026	NCT07600151	Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma	CD38 -- monoclonal antibody (isatuximab); Proteasome -- proteasome inhibitor (bortezomib); Cereblon -- immunomodulatory agent (lenalidomide); Glucocorticoid receptor -- corticosteroid (dexamethasone); Unknown mechanism (etentamig)
Dec 1, 2026	NCT07612787	A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma	BCMA -- CAR-T cells and bispecific antibody
Dec 2026	NCT07831122	Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)	BCMA + CD3 -- bispecific antibody (cevostamab); BCMA -- antibody-drug conjugate (belantamab mafodotin)

Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.